Delving into the Latest Updates on Schnengkang Medical Technology (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Cardiovascular Diseases

Infectious Diseases

siRNA

Oligonucleotide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

siRNA	3
Oligonucleotide	1

Top 5 Target	Count

AGT(Angiotensinogen)	1

主要目的：评估皮下注射 SNK-2726 在健康受试者和轻度血压升高受试者中的安全性和耐受性。次要目的：1. 评估皮下注射 SNK-2726 在健康受试者和轻度血压升高受试者中的药代动力学（PK）特征。2. 评估 SNK-2726 对血清中肾素-血管紧张素-醛固酮系统（RAAS）中血管紧张素原（AGT）的药效学（PD）作用。

[Translation]

Primary objective: To evaluate the safety and tolerability of subcutaneous administration of SNK-2726 in healthy subjects and subjects with mild hypertension. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of subcutaneous administration of SNK-2726 in healthy subjects and subjects with mild hypertension. 2. To evaluate the pharmacodynamic (PD) effect of SNK-2726 on angiotensinogen (AGT) in the renin-angiotensin-aldosterone system (RAAS) in serum.

Start Date-

Sponsor / Collaborator

Schnengkang Medical Technology (Suzhou) Co., Ltd.

NCT05896969

/ CompletedPhase 1

Phase 1, Single Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo Controlled Design to Investigate Safety, Tolerability, PK and PD of SC Administered SNK-396 in Subjects With Elevated Low-Density Lipoprotein Cholesterol

This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts:
SAD cohorts
MAD cohorts

Start Date27 Apr 2023

Sponsor / Collaborator

Syneos Health, Inc.

[+1]

100 Clinical Results associated with Schnengkang Medical Technology (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Schnengkang Medical Technology (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Schnengkang Medical Technology (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Schnengkang Medical Technology (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SNK-2726 ( AGT )	Essential Hypertension More	Phase 1
SNK-396	-	Phase 1
Infectious (Synerk)	Infectious Diseases More	Preclinical
Metabolic syndrome (Synerk)	Digestive System Disorders More	Preclinical